Biohaven
Develops prioritized drug programs in epilepsy, immunology, and obesity.
$15.16
After-hours close−0.24 (−1.56%)
At close$15.40(−4.47%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 96.02%Insiders 9.47%
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 150.56M · Float 123.75M · 82.2% free float
Institutions13F, as of Jun 30, 2026
308 holders · 144.57M shares · 53 new positions · 165 increased · 83 reduced · 35 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.21M | 8.77% | +1.99M | Aug 7, 2026 |
| Suvretta Capital Management, LLC | 10.29M | 6.83% | 0 | Aug 14, 2026 |
| Stifel Financial Corp | 9.94M | 6.60% | +280 | Aug 12, 2026 |
| Jupiter Topco LLC | 8.58M | 5.70% | +8.58Mnew | Aug 14, 2026 |
| Woodline Partners LP | 7.66M | 5.09% | +7.36M | Aug 14, 2026 |
| State Street Corp | 6.95M | 4.61% | +328.2K | Aug 7, 2026 |
| Infinitum Asset Management, LLC | 6.25M | 4.15% | 0 | Aug 14, 2026 |
| D. E. Shaw & Co., Inc. | 4.19M | 2.78% | +1.34M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 11.70% | 17.53M | 13G | May 15, 2026 ↗ |
| Suvretta Capital Management, LLC | 7.80% | 10.29M | 13G | Feb 13, 2026 ↗ |
| Woodline Partners LP | 5.10% | 7.66M | 13G | Aug 14, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| John Yetimoglu | director | 6.25M | 4.15% | Aug 14, 2026 |
| Vlad Coric | director, officer: Chief Executive Officer | 3.00M | 1.99% | Jan 7, 2026 |
| John W. Childs | director | 2.32M | 1.54% | Mar 9, 2026 |
| Gregory Bailey | director | 2.02M | 1.34% | Nov 17, 2025 |
| Warren Karl Volles | officer: Chief Legal Officer | 248.2K | 0.16% | Jul 17, 2026 |
| Matthew Buten | officer: Chief Financial Officer | 195.7K | 0.13% | Jan 7, 2026 |
| Kimberly Gentile | officer: SVP, Clinical Operations | 99.6K | 0.07% | Jan 7, 2026 |
| George C. Clark | officer: VP, Chief Accounting Officer | 87.0K | 0.06% | Jan 7, 2026 |
| Kishan Mehta | director | 22.7K | 0.02% | Mar 19, 2026 |
| Bruce Car | officer: Chief Scientific Officer | 7.7K | 0.01% | Jan 7, 2026 |
1 ten-percent owner holds 54.5K shares by Form 4, outside the officers-and-directors figure above · 13 people have not refiled in the last 18 months (2.84M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 4, 2025 | John W. Childsdirector | Purchase | 28,400 | $30.43 | 2,323,971 |
| Nov 17, 2025 | George C. Clarkofficer: VP, Chief Accounting Officer | Purchase | 17,000 | $8.52 | 20,000 |
| Nov 13, 2025 | Vlad Coricdirector, officer: Chief Executive Officer | Purchase | 333,333 | $7.50 | 1,195,275 |
| Nov 13, 2025 | John W. Childsdirector | Purchase | 3,333,333 | $7.50 | 5,653,904 |
| Nov 13, 2025 | Gregory Baileydirector | Purchase | 400,000 | $7.50 | 2,020,071 |
CongressHouse and Senate disclosures
Not reported.